Alpha 2.0
Login Register
» Articles » PMID: 38416423

The End of B/Yamagata Influenza Transmission - Transitioning from Quadrivalent Vaccines

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2024 Feb 28
PMID 38416423
Authors
Arnold S Monto
Maria Zambon
Jerry P Weir
Affiliations
Soon will be listed here.
Citing Articles

An mRNA vaccine candidate encoding cholera toxin subunit B and conserved antigens of influenza viruses confers cross-protection against influenza a viruses in adult and aged mice.

Xu L, Yu Z, Xu Y, Wang Q, Wang G, Li B Hum Vaccin Immunother. 2025; 21(1):2453304.

PMID: 39957235 PMC: 11834421. DOI: 10.1080/21645515.2025.2453304.

Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.

Finney J, Kuraoka M, Song S, Watanabe A, Liang X, Liao D bioRxiv. 2025; .

PMID: 39803488 PMC: 11722430. DOI: 10.1101/2025.01.01.631020.

Vaccinating against the absent: Risks of the B/Yamagata strain in the live attenuated vaccine.

Koul P Euro Surveill. 2024; 29(49).

PMID: 39639812 PMC: 11650483. DOI: 10.2807/1560-7917.ES.2024.29.49.2400766.

Influenza B Virus Vaccine Innovation through Computational Design.

Pekarek M, Weaver E Pathogens. 2024; 13(9).

PMID: 39338946 PMC: 11434669. DOI: 10.3390/pathogens13090755.

Prevalence of Influenza B/Yamagata Viruses From Season 2012/2013 to 2021/2022 in Italy as an Indication of a Potential Lineage Extinction.

Marchi S, Bruttini M, Milano G, Manini I, Chironna M, Pariani E Influenza Other Respir Viruses. 2024; 18(9):e13359.

PMID: 39257041 PMC: 11387461. DOI: 10.1111/irv.13359.